miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3
© 2014 Society for Endocrinology..
The expression and function of miR-145 in thyroid cancer is unknown. We evaluated the expression and function of miR-145 in thyroid cancer and its potential clinical application as a biomarker. We found that the expression of miR-145 is significantly downregulated in thyroid cancer as compared with normal. Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation, migration, invasion, VEGF secretion, and E-cadherin expression. miR-145 overexpression also inhibited the PI3K/Akt pathway and directly targeted AKT3. In vivo, miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model, and VEGF secretion. miR-145 inhibition in normal primary follicular thyroid cells decreased the expression of thyroid cell differentiation markers. Analysis of indeterminate fine-needle aspiration samples showed miR-145 had a 92% negative predictive value for distinguishing benign from malignant thyroid nodules. Circulating miR-145 levels were significantly higher in patients with thyroid cancer and showed a venous gradient. Serum exosome extractions revealed that miR-145 is secreted. Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Endocrine-related cancer - 21(2014), 4 vom: 30. Aug., Seite 517-31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boufraqech, Myriem [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.02.2015 Date Revised 21.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1530/ERC-14-0077 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM237814285 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM237814285 | ||
| 003 | DE-627 | ||
| 005 | 20231224112443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1530/ERC-14-0077 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0792.xml |
| 035 | |a (DE-627)NLM237814285 | ||
| 035 | |a (NLM)24781864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boufraqech, Myriem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3 |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2015 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 Society for Endocrinology. | ||
| 520 | |a The expression and function of miR-145 in thyroid cancer is unknown. We evaluated the expression and function of miR-145 in thyroid cancer and its potential clinical application as a biomarker. We found that the expression of miR-145 is significantly downregulated in thyroid cancer as compared with normal. Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation, migration, invasion, VEGF secretion, and E-cadherin expression. miR-145 overexpression also inhibited the PI3K/Akt pathway and directly targeted AKT3. In vivo, miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model, and VEGF secretion. miR-145 inhibition in normal primary follicular thyroid cells decreased the expression of thyroid cell differentiation markers. Analysis of indeterminate fine-needle aspiration samples showed miR-145 had a 92% negative predictive value for distinguishing benign from malignant thyroid nodules. Circulating miR-145 levels were significantly higher in patients with thyroid cancer and showed a venous gradient. Serum exosome extractions revealed that miR-145 is secreted. Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AKT3 | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a miR-145 | |
| 650 | 4 | |a thyroid cancer | |
| 650 | 7 | |a MIRN145 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a vascular endothelial growth factor A, mouse |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a AKT3 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Zhang, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Meenu |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dhaval |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Yin |e verfasserin |4 aut | |
| 700 | 1 | |a He, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Nilubol, Naris |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Maria J |e verfasserin |4 aut | |
| 700 | 1 | |a Kebebew, Electron |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine-related cancer |d 1997 |g 21(2014), 4 vom: 30. Aug., Seite 517-31 |w (DE-627)NLM093797834 |x 1479-6821 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2014 |g number:4 |g day:30 |g month:08 |g pages:517-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1530/ERC-14-0077 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2014 |e 4 |b 30 |c 08 |h 517-31 | ||